SalesCloser Technologies begins trading with over C$2M in annual recurring revenue and 6x growth A Vancouver-based artificial intelligence company has completed its public listing on the TSX Venture Exchange, bringing to…
Posts published in “Wall Street Wire”
Neurocrine Biosciences’ lightning-fast $2.9 billion takeover of Soleno Therapeutics (NASDAQ: SLNO) isn’t your typical biotech M&A deal. It’s a full-blown repricing event that just lit a fire under an entirely…
TL;DR: Alpha Tau (NASDAQ: DRTS) is emerging as a differentiated player in one of oncology’s fastest-growing areas – targeted radiation – but with a fundamentally different approach. Instead of competing…
Duke Robotics Corp*. (OTCQB: DUKRD) (ISIN: US9034482078) hat heute eine Nachricht veröffentlicht, die das Bild des 18-Millionen-Dollar-Unternehmens grundlegend verändern könnte: einen Millionen-Auftrag von der Israel Electric Corporation für drohnenbasierte Wartungs- und…
Battlefield-tested technology, a utility grid contract, and an AI product launch, all as a unprecedented war reshapes global defense priorities. Duke Robotics (OTCQB: DUKRD) is checking a lot of boxes…
TL;DR: Alpha Tau Medical Ltd. (NASDAQ: DRTS) is developing Alpha DaRT, a localized alpha-radiation therapy for solid tumors. Since late 2023, pharmaceutical giants have spent nearly $8 billion acquiring systemic…
As reimbursement tightens and capital returns, clinically validated wound care assets are becoming scarce – and strategically valuable One corner of healthcare quietly ballooned from a roughly $250 million Medicare…
Pancreatic cancer remains one of the deadliest diagnoses in medicine. While survival rates for many cancers have improved steadily over the past two decades, pancreatic cancer has lagged far behind.…
In a market crowded with early-stage medical device companies promising incremental improvements, Inspira Technologies (NASDAQ: IINN) stands out for a different reason. Rather than focusing on a single product or…
Newly announced expanded OPKO partnership set to advance oral hypoparathyroidism treatment candidate toward the clinic, adding momentum to a pipeline already approaching Phase 3 in osteoporosis Entera Bio’s latest announcement…